Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vd 2 T lymphocytes in non-hodgkin lymphomas

Haematologica

Volumn 99, Issue 1, 2014, Pages 131-139

  Musso, Alessandra ^a   Catellani, Silvia ^a   Canevali, Paolo ^b   Tavella, Sara ^a   Venè, Roberta ^a   Boero, Silvia ^a   Pierri, Ivana ^a   Gobbi, Marco ^a   Kunkl, Annalisa ^a   Ravetti, Jean Louis ^a   Zocchi, Maria Raffaella ^b   Poggi, Alessandro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DIFFERENTIATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; GENE EXPRESSION; HUMANS; IMMUNOLOGIC MEMORY; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MESENCHYMAL STROMAL CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; STROMAL CELLS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84892598990     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.097311     Document Type: Article

References (42)

1. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009;31(2):184-196.
2. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10(7): 467-478.
3. Das H, Wang L, Kamath A, Bukowski JF.V 9V 2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 2001;98(5):1616-1618.
4. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197(2):163-168.
5. Wang H, Sarikonda G, Puan K-J, Tanaka Y, Fenq J, Giner JL, et al. Indirect stimulation of human V 2V 2 T cells through alterations in isoprenoid metabolism. J Immunol. 2011; 187(10):5099-5113.
6. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci. USA 1999; 96(12):6879-6884.
7. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rael and HL60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165-171.
8. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gamma delta T cells. Science. 2001; 294(5542):605-609.
9. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class-I-related molecules, bind to CMV glicoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123-133.
10. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396.
11. Rincon-Orozoco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V 9V 2 T cells by NKG2D. J Immunol. 2005;175(4):2144 -2151.
12. Lafont V, Liautard J, Liautard J P, Favero J. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J Immunol. 2001;166 (12):7190-9.
13. Kunzman V, Bauer E, Feurle J, Weissinger F, Tony H P, Wilhelm M. Stimulation of T cells by aminobiphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood. 2000;96(2):384-92.
14. Ferrarini M, Ferrero E, Dagna L, Poggi A., Zocchi MR. Human g T cells: a nonredun-dant system in the immune-surveillance against cancer. Trends Immunol. 2002; 23(1):14-7.
15. Street SE, Hayakawa Y, Zhan Y, Lew AM, Mac Gregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphoma by natural killer and gammadelta T cells. J Exp Med. 2004;199(6):879-84.
16. Wilhelm M, Kunzman V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. T cells for immune therapy of patients. Blood. 2003;102(1):200-6.
17. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T lymphocytes in tumor immunology. Cancer Res. 2007;67(1):5-8.
18. Hannani D, Ma Y, Yamazaki T, De'Chanet-Merville J, Kroemer G, Zitvogel L. Harnessing. g T cells in anticancer immunotherapy. Trends Immunol. 2012; 33(5):199-206.
19. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector T cells and tumor cells as immune targets of zolen-dronic acid in multiple myeloma. Leukemia. 2005;19(4):664-670.
20. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007; 110(3):921-927.
21. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, et al. Bromohydrin pyrophos-phate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009; 113(20):4875-4884.
22. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of T lymphocyte effector functions by bisphos-phonate zolendronic acid in cancer patients in vivo. Blood. 2003;102(6):2310-2311.
23. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64(24):9172-9179.
24. Catellani S, Poggi A, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood. 2007;109(5):2078-2085.
25. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia. 2009; 23(4):641-648.
26. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, So HF, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rit-uximab and trastuzumab. Int J Cancer. 2008;122(11):2526-2534.
27. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, et al. Fc RIII discriminates between 2 subsets of V 9V 2 effector cells with different responses and activation pathways. Blood. 2004; 104(6):1801-1807.
28. Carbone A, Gloghini A, Cabras A, Elia G. The Germinal centre-derived lymphomas seen through their cellular microenviron-ment. Br J Haematol. 2009;145(4):468-480.
29. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499-3506.
30. Musso A, Zocchi MR, Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica. 2011;96(1):16-23.
31. Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D-ligands recognition in Hodgkin lymphomas. Blood. 2012;119(6):1479-1489.
32. Turner JJ, Morton LM, Linet MS, Clarke CA, Kladin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116(20):e90-98.
33. Ghio M, Contini P, Negrini S, Boero S, Musso A, Poggi A. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol. 2009;39(12):3459-3468.
34. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcrip-tase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.
35. Mosmann TR, Coffmann RL. TH1 and TH2 cells: different patterns of lymphocyte secretion lead to different functional properties. Annu Rev Immunol.1989;7:145-173.
36. Cua DJ, Kastelein RA. TGF-beta, a 'double agent' in the immune pathology war. Nat Immunol. 2006;7(6):557-559.
37. Capietto A-H, Martinet L, Cendron D, Fruchon S, Pont F, Fournié JJ. Phosphoantigen overcome human TCRV 9+ cell immunosuppression by TGF-: relevance for cancer immunotherapy. J Immunol. 2010;184(12):6680-6687.
38. Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. TGF- 1 and IL15 induce FoxP3+ regulatory T cells in the presence of antigen stimulation. J Immunol. 2009;183(6):3574-3577.
39. Prigione I, Benvenuto FG, Bocca P, Battistini L, Uccelli A, Pistoia V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009; 27(3):693-702.
40. Martinet L, Fleury-Cappellesso S, Gadelorge M, Dietrich G, Bourin F, Fournié JJ, et al. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mes-enchymal stem cells. Eur J Immunol. 2009; 39(3):752-762.
41. Chiplunkar S, Dhar S, Wesh D, Kabelitz D. T cells in cancer immunotherapy: current status and future prospects. Immunotherapy. 2009;1(4):663-678.
42. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64(20):7596-7603.